Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + Bevacizumab + Chemotherapy in Stage IV Non-squamous NSCLC
NCT03713944Phase 2Terminated
- Sponsor
- Nasser Hanna
- Start
- Nov 2018
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of atezolizumab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Nasser Hanna. Primary endpoint: Progression-Free Survival at 20 months. Started Nov 2018; status: terminated.
02
Drugs
atezolizumab
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT03713944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03713944.